Q3 EPS Forecast for Actinium Pharmaceuticals Cut by Analyst

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Research analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for Actinium Pharmaceuticals in a report issued on Monday, August 10th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.27) for the quarter, down from their previous forecast of ($0.24). The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at $0.12 EPS, FY2027 earnings at ($0.72) EPS and FY2028 earnings at ($0.75) EPS.

Actinium Pharmaceuticals Trading Up 3.0%

Shares of Actinium Pharmaceuticals stock opened at $0.79 on Wednesday. Actinium Pharmaceuticals has a 52 week low of $0.74 and a 52 week high of $1.81. The company’s 50-day moving average price is $0.94 and its two-hundred day moving average price is $1.09. The stock has a market cap of $24.88 million, a PE ratio of -0.57 and a beta of 0.01.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Actinium Pharmaceuticals in the 2nd quarter worth approximately $388,000. Jane Street Group LLC acquired a new stake in shares of Actinium Pharmaceuticals in the second quarter worth $306,000. Two Sigma Investments LP lifted its stake in shares of Actinium Pharmaceuticals by 403.4% in the third quarter. Two Sigma Investments LP now owns 234,293 shares of the company’s stock worth $375,000 after buying an additional 187,748 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Actinium Pharmaceuticals by 35.4% during the 4th quarter. Renaissance Technologies LLC now owns 390,784 shares of the company’s stock worth $531,000 after buying an additional 102,154 shares during the period. Finally, Marshall Wace LLP acquired a new position in Actinium Pharmaceuticals in the 2nd quarter valued at $137,000. 27.50% of the stock is owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.